Alkermes plc

ALKS Healthcare Drug Manufacturers Specialty & Generic

Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024. In the quarter to June 2026, revenue grew 27.0%, EPS fell 99.4% and free cash flow grew 1.13%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

41.22 1.12 +2.79%
Market cap
$6.7B
P/E
102×
Fwd P/E
−108×
Dividend yield
—
F-score
7/9
Altman Z
5.33
Beneish M
−3.29
Dividend safety
n/a

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Revenue
1,475.90 1,557.63 1,663.41 1,111.80 1,173.75 1,038.76 1,170.95 1,094.27 903.37 745.69
Revenue Growth
(5.25%) (6.36%) 49.61% (5.28%) 13.00% (11.29%) 7.01% 21.13% 21.15% 18.68%
Gross Profit
1,279.44 1,312.30 1,410.37 893.73 976.43 860.44 990.56 917.85 748.63 613.57
Operating Income
253.96 420.64 414.12 (6.09) 97.75 (112.43) (175.48) (99.13) (147.90) (208.66)
EBT
291.45 443.75 421.52 (31.13) 87.73 (96.54) (197.06) (126.97) (143.27) (214.39)
Income after Tax
241.66 372.14 519.16 (33.15) 76.40 (110.86) (196.62) (139.31) (157.94) (208.44)
Net Income Common
241.66 367.07 355.76 (158.27) (48.17) (110.86) (196.62) (139.31) (157.94) (208.44)
EPS (Diluted)
1.43 2.17 2.10 (0.97) (0.30) (0.70) (1.25) (0.90) (1.03) (1.38)
Shares (Diluted, Weighted)
168.74 169.20 169.73 163.74 164.75 158.80 157.05 155.11 153.42 151.48
Gross Margin
86.69% 84.25% 84.79% 80.39% 83.19% 82.83% 84.59% 83.88% 82.87% 82.28%
EBIT Margin
17.21% 27.00% 24.90% (0.55%) 8.33% (10.82%) (14.99%) (9.06%) (16.37%) (27.98%)
Net Profit Margin
16.37% 23.57% 21.39% (14.24%) (4.10%) (10.67%) (16.79%) (12.73%) (17.48%) (27.95%)
Free Cash Flow Margin
32.62% 26.07% 21.26% (1.55%) 6.22% 3.97% (1.53%) 2.77% (3.54%) (14.38%)
EBITDA
281.12 449.17 489.05 71.77 176.40 (30.57) (95.07) 4.53 (49.38) (114.41)
EBIT
253.96 420.64 414.12 (6.09) 97.75 (112.43) (175.48) (99.13) (147.90) (208.66)

Show all line items

In millions of $ except per-share values · columns are period end dates